Description
KQB365 is an experimental medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being investigated by Kumquat Biosciences Inc. The goal of the trials is to determine the safe dosage of KQB365, both when given alone and in combination with cetuximab (a standard treatment for some colorectal cancers), and to see if it can shrink tumors. The trials are in Phase 1, which means they primarily focus on safety and determining the best way to give the drug. The trials are currently recruiting participants. One trial specifically includes patients with colorectal cancer whose tumors have a specific type of KRAS mutation (G12S). KQB365 is not yet approved for treating colorectal cancer.
Mechanism of Action
The specific way KQB365 works (its mechanism of action) is still being investigated in clinical trials. It is being studied as both a single treatment (monotherapy) and in combination with cetuximab. Researchers are looking to understand how the drug affects the body and how it might impact tumor growth.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.